Document is current
Any future updates will be listed below
-
Authors
Sherry, Alexander D.
Liu, Yufei
Msaouel, Pavlos
Lin, Timothy A.
Koong, Alex
Lin, Christine
Abi Jaoude, Joseph
Patel, Roshal R.
Kouzy, Ramez
El-Alam, Molly B.
Miller, Avital M.
Owiwi, Mohannad
Ofer, Jonathan
Bomze, David
McCaw, Zachary R.
Meirson, Tomer
Ludmir, Ethan B.
-
Funding
Funding for this research was provided by:
Andrew Sabin Family Foundation
National Institutes of Health (P30CA016672)
- License Information
-
More Information
Article History
Received: 14 January 2025
Accepted: 21 June 2025
First Online: 24 July 2025
Competing interests
: A.S. reports honoraria from Sermo. P.M. reports honoraria for scientific advisory board membership for Mirati Therapeutics, Bristol-Myers Squibb, and Exelixis; consulting fees from Axiom Healthcare; non-branded educational programs supported by DAVA Oncology, Exelixis, and Pfizer; leadership or fiduciary roles as a Medical Steering Committee Member for the Kidney Cancer Association and as a Kidney Cancer Scientific Advisory Board Member for KCCure; and research funding from Regeneron Pharmaceuticals, Takeda, Bristol-Myers Squibb, Mirati Therapeutics, and Gateway for Cancer Research (all unrelated to this manuscript’s content). Z.M. reports employment at Insitro (unrelated to this manuscript’s content). T.M. reports consulting fees from Purple Biotech. No other authors report any conflicts of interest.
